For talimogene laherparepvec (Imlygic®), a genetically modified herpes simplex virus (HSV) for tumor lysis, beperminogene perplasmid (Collategene®), a plasmid-coding hepatocyte growth factor, and onasemnogene abeparvovec-xioi (Zolgensma®), a genetically modified adeno-associated virus 9, no studies have investigated whether host cells immunologically recognize these drugs as foreign substances. Here, HGF is linked to neoplasm.